Floatz logo

Autologous Apd-L1 Armored Anti-Cd22 Car T Cells

Cervical Cancer

Hebei Senlang Biotechnology Inc., Ltd.Cell therapyPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

160 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Indocyanine Green
Istanbul University
Phase 4BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B
Carboplatin
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

Autologous Apd-L1 Armored Anti-Cd22 Car T Cells is also rated in:

sarcomaDormant
C
Indicative ·
39 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →